Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunoablation plus autologous hematopoietic stem cell transplantation versus standard immunosuppressive therapy for refractory systemic lupus erythematosus
2006-001269-40Phase 2Active
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2008
- Modality
- Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of antithymocyte globulin and cyclophosphamide in systemic lupus erythematosus (SLE) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Complete clinical remission at Month 24. Started Mar 2008; status: active.
02
Drugs
antithymocyte globulincyclophosphamide
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2006-001269-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001269-40.